B Cell News and Research

RSS

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Researchers tested whether a subunit vaccine could generate mucosal immunity in mice and prevent SARS-CoV-2 infection and related pathology.

11 Apr 2022

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

Researchers performed high-throughput evolutionary analyses of genes encoding 334 SARS-CoV-2 viral-interacting proteins of modern humans, primates, and bats.

11 Apr 2022

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

11 Apr 2022

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Researchers identified an ultralong bovine antibody that neutralizes SARS-CoV-2 and SARS-CoV.

11 Apr 2022

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

A new study depicted plant-based biologically active antiviral agents that are effective against SARS-CoV-2 infection.

11 Apr 2022

What does the Future of Microfluidics within Research Look Like?

We speak to France Hamber, CEO of Fluigent, about their microfluidics solutions and how they are allowing scientists to focus more on the science than the setup.

From Fluigent 11 Apr 2022

Let’s Talk about Parkinson’s

In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

The effect of unsuppressed HIV on T-cell response to COVID-19

A new study evaluates the impact of HIV infection on SARS-CoV-2 T-cell responses during the first and second waves of COVID-19 in South Africa.

10 Apr 2022

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Researchers identify a potentially effective compound against COVID-19 against the SARS-CoV-2 PLpro.

10 Apr 2022

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Researchers assess the impact of interval administration of LD-IL-2 was examined in 18 T1D patients who received a three-day dosing interval.

10 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

MOFs could help improve the delivery of genetic cargo into target cells

Hybrid material helps ferry genetic cargo to target cells. An emerging type of material called a metal-organic framework(MOF) could help improve the delivery of genetic material for treating disease.

10 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

B Cell News and Research

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

What does the Future of Microfluidics within Research Look Like?

Let’s Talk about Parkinson’s

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

Immunocompromised hosts with Delta/Omicron co-infections

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

The effect of unsuppressed HIV on T-cell response to COVID-19

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

MOFs could help improve the delivery of genetic cargo into target cells

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News